FUKUHARA TATSURO 福原達朗

… Alternative Names

福原達朗フクハラタツロウ

FUKUHARA Tatsuro 福原達朗

Less

Researcher Number	80400365
Affiliation (Current)	2023: 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん先進治療開発研究部, 特任研究員
Affiliation (based on the past Project Information) *help	2020 – 2021: 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん先進治療開発研究部, 特任研究員 2016 – 2018: 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん先進治療開発研究部, 特任研究員 2012: 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん先進治療開発研究部, 特任研究員 2012: 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), その他部局等, その他 2011: 東北大学, 大学病院, 助教 2007 – 2011: Tohoku University, 病院, 助教 2005 – 2006: 東北大学, 病院・医員
Review Section/Research Field	Principal Investigator Respiratory organ internal medicine / Basic Section 53030:Respiratory medicine-related Except Principal Investigator Respiratory organ internal medicine
Keywords	Principal Investigator 癌 / EGFR / 肺癌 / SLPI / アディポカイン / 発癌 / cell senescellce / EGFR変異陽性肺癌 / 非小細胞肺がん / 好中球 … More / 非小細胞肺癌 / 抗腫瘍免疫 / がん / 細胞骨格 … More Except Principal Investigator 肺腺癌 / EGF受容体 / 非喫煙者 / ゲノム / 東アジア / EGFR遺伝子変 / ゲノム解析研究 / EGFR受容体 / 細気管支上皮細胞 / 不死化 / 発癌 / がん遺伝子依存 / 分子標的薬 / 細胞内シグナル伝達 / EGF receptor / lung adenocarcinoma / bronchiolar epithelial cell / anti-apoptotic / tumorigenesis / oncogene addiction / molecular targeting drugs / intracellular signaling Less

Cytoskeleton-YAP axis regulates lung cancer resistanc: From mechanism to therapyPrincipal Investigator
- Principal Investigator
  
  福原達朗
- Project Period (FY)
  2020 – 2022
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 53030:Respiratory medicine-related
- Research Institution
  Miyagi Prefectural Hospital Organization Miyagi Cancer Center
Tumor associated Neutrophils control NSCLC-Immune interfacePrincipal Investigator
- Principal Investigator
  
  FUKUHARA TATSURO
- Project Period (FY)
  2016 – 2018
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Respiratory organ internal medicine
- Research Institution
  Miyagi Prefectural Hospital Organization Miyagi Cancer Center
Why EGFR-mutant positive cancer preferentially arise from lung?Principal Investigator
- Principal Investigator
  
  FUKUHARA Tatsuro
- Project Period (FY)
  2011 – 2012
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Respiratory organ internal medicine
- Research Institution
  地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所)
  Tohoku University
Biological background for non-smoker lung adenocarcinoma : Why do EGFR somatic mutations accumulate on lung adenocarcinoma and on Asian ethnics?
- Principal Investigator
  
  NUKIWA Toshihiro
- Project Period (FY)
  2009 – 2011
- Research Category
  
  Grant-in-Aid for Scientific Research (A)
- Research Field
  
  Respiratory organ internal medicine
- Research Institution
  Tohoku University
Regulation of adipokine by SLPIPrincipal Investigator
- Principal Investigator
  
  FUKUHARA Tatsuro
- Project Period (FY)
  2007 – 2008
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Respiratory organ internal medicine
- Research Institution
  Tohoku University
Activation mutations in EGF receptor kinase have the advantages of cell physiology in the bronchiolar region : Implication of anti-apoptotic signals and lung tumorigenesis and metastasis.
- Principal Investigator
  
  NUKIWA Toshihiro
- Project Period (FY)
  2005 – 2006
- Research Category
  
  Grant-in-Aid for Scientific Research (B)
- Research Field
  
  Respiratory organ internal medicine
- Research Institution
  TOHOKU UNIVERSITY

All 2022 2021 2020 2019 2018 2017 2016 2012 2011 2010 2009 2008 2007

All Journal Article Presentation

[Journal Article] First-line nivolumab+ ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients2022
- Author(s)
  O’Byrne K.J.、Lee K.H.、Kim S.-W.、Park K.、Nishio M.、Sakai H.、Ohe Y.、Fukuhara T.、Kang J.-H.、Daga H.、Yu C.-J.、Hotta K.、Tanaka H.、Takeda M.、Yokoyama T.、Nathan F.E.、Lee J.-S.
- Journal Title
  
  ESMO Open
  
  Volume: 7 Pages: 100394-100394
- DOI
  10.1016/j.esmoop.2022.100394
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K08580
[Journal Article] Phase II study of carboplatin-paclitaxel alone or with bevacizumab in advanced sarcomatoid carcinoma of the lung: HOT1201/NEJ0242022
- Author(s)
  Oizumi Satoshi、Takamura Kei、Harada Toshiyuki、Tachihara Motoko、Morikawa Naoto、Honda Ryoichi、Watanabe Satoshi、Asao Tetsuhiko、Kunisaki Mamoru、Fukuhara Tatsuroら, Hokkaido Lung Cancer Clinical Study Group
- Journal Title
  
  International Journal of Clinical Oncology
  
  Volume: 27 Pages: 676-683
- DOI
  10.1007/s10147-021-02113-5
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K08580
[Journal Article] MK‐6, a novel not‐α IL‐2, elicits a potent antitumor activity by improving the effector to regulatory T cell balance2021
- Author(s)
  Kobayashi Maki、Kojima Katsuhiko、Murayama Kazutaka、Amano Yuji、Koyama Takashi、Ogama Naoko、Takeshita Toshikazu、Fukuhara Tatsuro、Tanaka Nobuyuki
- Journal Title
  
  Cancer Science
  
  Volume: 112 Pages: 4478-4489
- DOI
  10.1111/cas.15127
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K08203, KAKENHI-PROJECT-20K08580, KAKENHI-PROJECT-21K08795
[Journal Article] Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancer.2021
- Author(s)
  Ito Takashi、Nagashima Hiromi、Akiyama Masachika、Utsumi Yu、Sato Hideomi、Chiba Shinji、Sugai Mayu、Ube Kenji、Mori Yoshiaki、Watanabe Kana、Fukuhara Tatsuro、Maemondo Makoto
- Journal Title
  
  Thoracic Cancer
  
  Volume: 13 Pages: 386-393
- DOI
  10.1111/1759-7714.14267
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K08580
[Journal Article] Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first‐line induction therapy for extensive disease small cell lung cancer.2021
- Author(s)
  Tanaka Hisashi、Hasegawa Yukihiro、Fujita Yuka、Nakamura Atsushi、Kikuchi Eiki、Kawai Yasutaka、Harada Toshiyuki、Watanabe Naomi、Yokouchi Hiroshi、Usui Kazuhiro、Saito Ryota、Watanabe Hiroshi、Masuda Tomomi、Fukuhara Tatsuro、Kudo Keita、Honda Ryoichi、Oizimi Satoshi、Maemondo Makoto、Inoue Akira、Morikawa Naoto
- Journal Title
  
  Thoracic Cancer
  
  Volume: 12 Pages: 2113-2121
- DOI
  10.1111/1759-7714.14048
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K08580
[Journal Article] First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset2021
- Author(s)
  Satouchi Miyako、Nosaki Kaname、Takahashi Toshiaki、Nakagawa Kazuhiko、Aoe Keisuke、Kurata Takayasu、Sekine Akimasa、Horiike Atsushi、Fukuhara Tatsurora
- Journal Title
  
  Cancer Science
  
  Volume: 112 Pages: 5000-5010
- DOI
  10.1111/cas.15144
- NAID
  120007170522
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K08580
[Journal Article] Randomized phase II trial of uracil/tegafur and cisplatin versus pemetrexed and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-squamous non-small cell lung cancer: NJLCG10012021
- Author(s)
  K.Watanabe, Y.Toi, A.Nakamura, R.Chiba, M.Akiyama, J.Sakakibara-Konishi, H.Tanaka, N.Yoshimura, E.Miyauchi, T.Nakagawa, R.Igusa, H.Minemura, Y.Mori, K.Fujimoto, H.Matsushita, F.Takahashi, T.Fukuhara, A.Inoue, S.Sugawara, M.Maemonndo
- Journal Title
  
  Translational Lung Cancer Research
  
  Volume: 10 Pages: 712-722
- DOI
  10.21037/tlcr-20-721
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20K08580, KAKENHI-PROJECT-17H04149
[Journal Article] The CLIP1-LTK fusion is an oncogenic driver?in non‐small‐cell lung cancer2021
- Author(s)
  Izumi Hiroki、Matsumoto Shingo、Liu Jie、Tanaka Kosuke、Mori Shunta、Hayashi Kumiko、Kumagai Shogo、Shibata Yuji、Hayashida Takuma、Watanabe Kana、Fukuhara Tatsuroら
- Journal Title
  
  Nature
  
  Volume: 600 Pages: 319-323
- DOI
  10.1038/s41586-021-04135-5
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K08580
[Journal Article] First-line pemburilizumzb vs chemotherarapy in metastatic non-small-cerll lung cancer: KEYNOTE-024 japan subset.2020
- Author(s)
  M.Satouchi, K.Nosaki, T.Takahashi, K.Nakagawa, K.Aoe, T.Kurata, A.Sekine, A.Horiike, T.Fukuhara, S.Sugawara, S.Umemura, H.Saka, I.Okamoto, N.Yamamoto, H.Sakai, K.Kishi, N.Katakami, H.Horinouti, T.Hida, H.Okamoto, S.Atagi, T.Ohira, S.Rong Han, K.Noguchi, V,Ebiana, K.Hotta
- Journal Title
  
  Cancer Science
  
  Volume: 111 Pages: 4480-4489
- DOI
  10.1111/cas.14647
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20K08580
[Journal Article] Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study.2020
- Author(s)
  T.Fukuhara, H.Saito, N.Furuya, K.Watanabe, S.Sugawara, S.Iwasawa, Y.Tsunezuka, O.Yamaguchi, M.Okada, K.Yoshimori, I.Nakachi, A.Genma, K.Azuma, F.Kurimoto, Y.Tsubata, Y.Fijita, H.Nagashima, G.Asai, S.Watanabe, M.Miyazaki, K.Hagiwara, T.Nukiwa, S.Morita, K.Kobayashi, M.Maemondo
- Journal Title
  
  EBioMedicine
  
  Volume: 57 Pages: 102861-102861
- DOI
  10.1016/j.ebiom.2020.102861
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20K08580
[Journal Article] Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial2019
- Author(s)
  Saito Haruhiro、Fukuhara Tatsuro、Maemondo Makotoら
- Journal Title
  
  The Lancet Oncology
  
  Volume: 20 Pages: 625-635
- DOI
  10.1016/s1470-2045(19)30035-x
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-16K09597
[Journal Article] PKM1 Confers Metabolic Advantages and Promotes Cell-Autonomous Tumor Cell Growth2018
- Author(s)
  M Morita, T Sato, M Nomura, Y Sakamoto, Y Inoue, R Tanaka, S Ito, K Kurosawa, K Yamaguchi, Y Sugiura, H Takizaki, Y Yamashita, R Katakura, I Sato, Y Okada, H Watanabe, G Kondoh, et al.
- Journal Title
  
  Cancer Cell
  
  Volume: 12 Pages: 355-367
- DOI
  10.1016/j.ccell.2018.02.004
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-16K07296, KAKENHI-PROJECT-16K09597, KAKENHI-PROJECT-16K10486, KAKENHI-PROJECT-17K19620, KAKENHI-PROJECT-17K16876, KAKENHI-PLANNED-25111006, KAKENHI-PROJECT-16H04730, KAKENHI-PROJECT-15K09237, KAKENHI-PROJECT-15K21098, KAKENHI-PROJECT-16K19745, KAKENHI-PROJECT-17K07187, KAKENHI-PUBLICLY-17H05534, KAKENHI-PUBLICLY-17H06011, KAKENHI-PROJECT-16K10774, KAKENHI-PROJECT-17K19606, KAKENHI-PLANNED-17H06301
[Journal Article] Relapsed Myasthenia Gravis after Nivolumab Treatment2018
- Author(s)
  Mitsune Ayumi、Yanagisawa Satoru、Fukuhara Tatsuro、Miyauchi Eisaku、Morita Mami、Ono Manabu、Tojo Yutaka、Ichinose Masakazu
- Journal Title
  
  Internal Medicine
  
  Volume: 9153 Issue: 13 Pages: 1893-1897
- DOI
  10.2169/internalmedicine.9153-17
- NAID
  130007387159
- ISSN
  0918-2918, 1349-7235
- Language
  English
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-16K09597, KAKENHI-PROJECT-16H05307
[Journal Article] EGFR Mutation Analysis of Circulating Tumor DNA Using an Improved PNA-LNA PCR Clamp Method2016
- Author(s)
  Watanabe K, Fukuhara T, Tsukita Y, Morita M, Suzuki A, Tanaka N, Terasaki H, Nukiwa T, Maemondo M
- Journal Title
  
  Can Respir J.
  
  Volume: 5297329 Pages: 5297329-5297329
- DOI
  10.1155/2016/5297329
- Peer Reviewed / Acknowledgement Compliant / Open Access
- Data Source
  KAKENHI-PROJECT-15K14414, KAKENHI-PROJECT-16K09597, KAKENHI-PROJECT-15K09237
[Journal Article] Ann Oncol2010
- Author(s)
  Inoue A, Ishimoto 0, Fukumoto S, Usui K, Suzuki T, Yokouchi H, Maemondo M, Kanbe M, Ogura S, Harada T, Oizumi S, Harada M, Sugawara S, Fukuhara T, Nukiwa T(North Japan Lung Cancer Study Group trial 0405 )
- Journal Title
  
  A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer.
  
  Volume: 21 Pages: 800-803
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21249052
[Journal Article] A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer : North Japan Lung Cancer Study Group Trial 04052010
- Author(s)
  Inoue A, Ishimoto O, Fukumoto S, Usui K, Suzuki T, Yokouchi H, Maemondo M, Kanbe M, Ogura S, Harada T, Oizumi S, Harada M, Sugawara S, Fukuhara T, Nukiwa T
- Journal Title
  
  Ann Oncol
  
  Volume: 21 Pages: 800-803
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21249052
[Journal Article] (North Japan Lung Cancer Study Group trial 0405): A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer2009
- Author(s)
  Inoue A, Ishimoto O, Fukumoto S, Usui K, Suzuki T, Yokouchi H, Maemondo M, Kanbe M, Ogura S, Harada T, Oizumi S, Harada M, Sugawara S, Fukuhara T, Nukiwa T
- Journal Title
  
  Ann Oncol
  
  Volume: 21 Pages: 800-803
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21249052
[Journal Article] Suppression of surfactant protein A by an epidermal growth factor receptor tyrosine kinase inhibitor exacerbates lung innammation.2008
- Author(s)
  Inoue A, Xin H, Suzuki T, Kanehira M, Kuroki Y, Fukuhara T, 他4名
- Journal Title
  
  Cancer Sci. Aug
  
  Pages: 1679-1684
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-19790551
[Journal Article] Secretory leukocyte peptidase inhibitor and lung cancer.2008
- Author(s)
  Nukiwa T, Suzuki T, Fukuhara T, Kikuchi T
- Journal Title
  
  Cancer Sci. May
  
  Pages: 849-855
- NAID
  10024005504
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-19790551
[Presentation] Overall survival and ctDNA analysis of bevacizumab plus erlotinib treatment for EGFR-mutant NSCLC patients in NEJ0262021
- Author(s)
  福原達朗, 古谷直樹, 齋藤春洋, 渡邉香奈, 菅原俊一, 岩沢俊一郎, 常塚宣男, 山口央, 岡田守人, 吉森浩三, 仲地一郎, 弦間昭彦, 東公一, 萩原弘一, 貫輪敏博, 森田智視, 小林国彦, 前門戸任
- Organizer
  第18回日本臨床腫瘍学会学術集会
- Invited
- Data Source
  KAKENHI-PROJECT-20K08580
[Presentation] A novel not-α IL-2 elicits potent anti-tumor activity in mice by improving the effector to regulatory T cell balance.2021
- Author(s)
  小林真紀、小鎌直子、小嶋克彦、福原達朗、田中伸幸
- Organizer
  第79回日本癌学会学術総会
- Data Source
  KAKENHI-PROJECT-20K08580
[Presentation] A Prospective Observational Study of Osimertinib Using Plasma Concentrations in NSCLC With Acquired EGFR T790M Mutation.2021
- Author(s)
  T. Nakagawa, T. Fukuhara, K. Imai, R. Igusa, H. Yokota, K. Watanabe, A. Suzuki, M. Morita, A. Inoue, M. Miura, Y. Minamiya, M. Maemondo
- Organizer
  2021 World Conference on Lung Cancer
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-20K08580
[Presentation] First-line pemburilizumzb vs chemotherarapy in metastatic non-small-cerll lung cancer: KEYNOTE-024 japan subse2020
- Author(s)
  KJ O'Byrne, KH Lee, S-W Kim, K Park, M Nishio, H Sakai, Y Ohe, T Fukuhara, J Kang, H Daga, M Takeda, T Yakoyama, FE Nathan, JLee
- Organizer
  ESMO Virtual
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-20K08580
[Presentation] EGFR阻害薬で治療された腫瘍におけるT790M耐性変異および活性型変異のシスおよびトランス頻度2020
- Author(s)
  平野邦夫, 渡邉香奈, 秋山真親, 千葉亮祐, 長島広相, 佐藤英臣, 菅井万優, 寺崎浩司, 福原達朗, 前門戸
- Organizer
  第61回日本肺癌学会学術集会
- Data Source
  KAKENHI-PROJECT-20K08580
[Presentation] Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations (NEJ026)2020
- Author(s)
  M Maemondo, T Fukuhara, H Saito, N Furuya, K Watanabe, S Sugawara, S Iwasawa, Y Tsunezuka, O Yamaguchi, M Okada, K Yoshimori, I Nakachi, A Genma, K Azuma, K Hagiwara, T Nukiwa, S Morita, K Kobayashi
- Organizer
  ASCO Annual Meeting Virtual
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-20K08580
[Presentation] Updated survival outcomes of NEJ005/TCOG0902, a randomized PII of gefitinid and chemotherapy in EGFR-mutant NSCLC2017
- Author(s)
  Tatsuro Fukuhara, Satoshi Oizumi, Shunichi Sugawara, Koichi Minato, Toshiyuki Harada, Akira Inoueら
- Organizer
  18th World Conference on Lung Cancer
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-16K09597
[Presentation] 高濃度イマチニブはゲフィチニブ耐性化したEGFR変異陽性肺癌細胞の増殖を阻害する2012
- Author(s)
  福原達朗、トレダセザリー、井上彰、海老名雅仁、貫和敏博
- Organizer
  第52回日本呼吸器学会学術講演会
- Place of Presentation
  神戸
- Data Source
  KAKENHI-PROJECT-23790892
[Presentation] Imatinib treatment for gefitinib resistant epidermal growth factor receptor-mutant lung cancer2012
- Author(s)
  Tatsuro Fukuhara, Cezary Jan Treda, Tomohiro Sakakibara, Akira Inoue, Masahito Ebina, Toshihiro Nukiwa
- Organizer
  American Association for Cancer Reserch, Annual Meeting
- Place of Presentation
  Chicago
- Data Source
  KAKENHI-PROJECT-23790892
[Presentation] 高濃度イマチニブはゲフィチニブ耐性化したEGFR変異陽性肺癌細胞の増殖を阻害する2012
- Author(s)
  福原達朗、トレダセザリー、井上彰、海老名雅仁、貫和敏博
- Organizer
  第５２回日本呼吸器学会学術講演会
- Place of Presentation
  神戸市
- Data Source
  KAKENHI-PROJECT-23790892
[Presentation] Imatinib treatment for gefitinib resistant epidermal growth factor receptor-mutant lung cancer2012
- Author(s)
  Tatsuro Fukuhara, Cezary Jan Treda, Tomohiro Sakakibara, Akira Inoue, Masahito Ebina, Toshihiro Nukiwa
- Organizer
  American Association for Cancer Reserch, Annual Meeting
- Place of Presentation
  Chicago, USA
- Data Source
  KAKENHI-PROJECT-23790892
[Presentation] Clinical Aspects Of Non-Small Cell Lung Cancer Harboring EML4-ALK Fusion Gene In Tohoku University Hospital2011
- Author(s)
  Sakakibara T, Inoue A, Fukuhara T, Sasaki T, Nukiwa T
- Organizer
  American Thoracic Society International Conference
- Place of Presentation
  Denver
- Year and Date
  2011-05-15
- Data Source
  KAKENHI-PROJECT-21249052
[Presentation] 肺癌細胞株PC9(EGFR deletion)とA549(k-ras ser)におけるside population, self seeding, 肺Xenograft形成2010
- Author(s)
  貫和紀子, 謝勉, 福原達朗, トレダセザリ, 菊地利明, 海老名雅仁, 貫和敏博
- Organizer
  第69回日本癌学会学術講演会
- Place of Presentation
  大阪
- Year and Date
  2010-09-22
- Data Source
  KAKENHI-PROJECT-21249052
[Presentation] Xenograft Formation, Self Seeding, and Side Population in Lung Adenocarcinoma Cell Lines, PC9(EGFR deletion)and A549(k-rasSer).2010
- Author(s)
  Nukiwa N, Xie M, Fukuhara T, Treda C, Kikuchi T, Ebina M, Nukwa T
- Organizer
  European Respiratory Society 2010
- Place of Presentation
  Barcelona, Spain
- Year and Date
  2010-09-21
- Data Source
  KAKENHI-PROJECT-21249052
[Presentation] 肺癌細胞株PC9(EGFR deletion)とA549(k-ras Ser)におけるside population, selfseeding,肺xenograft形成.2010
- Author(s)
  貫和紀子, 謝勉, 福原達朗, トレダセザリ, 菊地利明, 海老名雅仁, 貫和敏博
- Organizer
  第69回日本癌学会学術講演会
- Place of Presentation
  大阪
- Year and Date
  2010-09-23
- Data Source
  KAKENHI-PROJECT-21249052
[Presentation] Xenograft Formation, Self Seeding, and Side Population in Lung Adenocarcinoma Cell Lines, PC9 (EGFR deletion)and A549 (k-ras Ser)2010
- Author(s)
  Nukiwa N, Xie M, Fukuhara T, Treda C, Kikuchi T, Ebina M, Nukwa T
- Organizer
  European Respiratory Society 2010
- Place of Presentation
  Barcelona
- Year and Date
  2010-09-15
- Data Source
  KAKENHI-PROJECT-21249052
[Presentation] 蛋白分解酵素阻害物質Secretory leukoprotease inhibitor(SLPI)の肺癌形成における役割2008
- Author(s)
  福原達朗, 鈴木拓児, 他
- Organizer
  日本癌学会
- Place of Presentation
  名古屋国際会議場
- Year and Date
  2008-10-28
- Data Source
  KAKENHI-PROJECT-19790551
[Presentation] 蛋白分解酵素阻害物質Secretory leukoprotease inhibitor (SLPI)の肺癌形成における役割2008
- Author(s)
  福原達朗、鈴木拓児他
- Organizer
  日本癌学会
- Place of Presentation
  名古屋
- Year and Date
  2008-10-28
- Data Source
  KAKENHI-PROJECT-19790551
[Presentation] 蛋白分解酵素阻害物質Secretory leukoprotease inhibitor (SLPI)による肺癌形成促進の機序2007
- Author(s)
  福原達朗、鈴木拓児他
- Organizer
  日本癌学
- Place of Presentation
  千葉
- Year and Date
  2007-10-04
- Data Source
  KAKENHI-PROJECT-19790551
[Presentation] 蛋白分解酵素阻害物質Secretory leukoprotease inhibitor (SLPI)による肺癌形成促進の機序2007
- Author(s)
  福原達朗, 鈴木拓児, 他
- Organizer
  日本癌学会
- Place of Presentation
  横浜幕張メッセ
- Year and Date
  2007-10-04
- Data Source
  KAKENHI-PROJECT-19790551

1. NUKIWA Toshihiro (40129036)

# of Collaborated Projects: 2 results

# of Collaborated Products: 8 results
2. INOUE Akira (70361087)

# of Collaborated Projects: 2 results

# of Collaborated Products: 5 results
3. 前門戸任 (40344676)

# of Collaborated Projects: 2 results

# of Collaborated Products: 3 results
4. 田中伸幸 (60280872)

# of Collaborated Projects: 2 results

# of Collaborated Products: 8 results
5. EBINA Masahito (10280885)

# of Collaborated Projects: 1 results

# of Collaborated Products: 4 results
6. KIKUCHI Toshiaki (10280926)

# of Collaborated Projects: 1 results

# of Collaborated Products: 4 results
7. SAKAKIBARA Tomohiro (80422111)

# of Collaborated Projects: 1 results

# of Collaborated Products: 1 results
8. HAGIWARA Kouichi (00240705)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
9. SUZUKI Takuji (80344670)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
10. NISHIO Kazuto (10208134)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
11. KANEHIRA Masahiko (90374941)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
12. 長島隆一 (20783707)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
13. KAWAI Masaaki

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
14. 竹下敏一

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
15. 小嶋克彦

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
16. 渡辺利雄

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
17. 島礼

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
18. 田沼延公

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
19. 渡邊仁美

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
20. 井上維

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
21. 佐藤郁郎

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
22. 山下洋二

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
23. 中山敬一

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
24. 一ノ瀬正和

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results

FUKUHARA TATSURO 福原 達朗

福原 達朗 フクハラ タツロウ

FUKUHARA Tatsuro 福原 達朗

Research Projects

Research Products

Co-Researchers

Cytoskeleton-YAP axis regulates lung cancer resistanc: From mechanism to therapyPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Tumor associated Neutrophils control NSCLC-Immune interfacePrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Why EGFR-mutant positive cancer preferentially arise from lung?Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Biological background for non-smoker lung adenocarcinoma : Why do EGFR somatic mutations accumulate on lung adenocarcinoma and on Asian ethnics?

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Regulation of adipokine by SLPIPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Activation mutations in EGF receptor kinase have the advantages of cell physiology in the bronchiolar region : Implication of anti-apoptotic signals and lung tumorigenesis and metastasis.

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Journal Article] First-line nivolumab+ ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Phase II study of carboplatin-paclitaxel alone or with bevacizumab in advanced sarcomatoid carcinoma of the lung: HOT1201/NEJ0242022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] MK‐6, a novel not‐α IL‐2, elicits a potent antitumor activity by improving the effector to regulatory T cell balance2021

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancer.2021

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first‐line induction therapy for extensive disease small cell lung cancer.2021

Author(s)

Journal Title

DOI

Data Source

[Journal Article] First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset2021

Author(s)

Journal Title

DOI

NAID

Data Source

[Journal Article] Randomized phase II trial of uracil/tegafur and cisplatin versus pemetrexed and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-squamous non-small cell lung cancer: NJLCG10012021

Author(s)

Journal Title

DOI

Data Source

[Journal Article] The CLIP1-LTK fusion is an oncogenic driver?in non‐small‐cell lung cancer2021

Author(s)

FUKUHARA TATSURO 福原達朗

福原達朗フクハラタツロウ

FUKUHARA Tatsuro 福原達朗